This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2020 Oct 14;22(10):1422-1424.

doi: 10.1093/neuonc/noaa142.

Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery

Stuart A Grossman¹, Carlos G Romo¹, Michelle A Rudek¹, Jeffrey Supko², Joy Fisher¹, L Burt Nabors³, Patrick Y Wen⁴, David M Peereboom⁵, Benjamin M Ellingson⁶, William Elmquist⁷, Fred G Barker², David Kamson¹, Jann N Sarkaria⁸, William Timmer⁹, Ranjit S Bindra¹⁰, Xiaobu Ye¹

Affiliations

Affiliations

¹ Johns Hopkins University, Baltimore, Maryland.
² Massachusetts General Hospital, Boston, Massachusetts.
³ University of Alabama Birmingham, Birmingham, Alabama.
⁴ Dana-Farber Cancer Institute, Boston, Massachusetts.
⁵ Cleveland Clinic, Cleveland, Ohio.
⁶ University of California Los Angeles, Los Angeles, California.
⁷ University of Minnesota, Minneapolis, Minnesota.
⁸ Mayo Clinic, Rochester, Minnesota.
⁹ National Cancer Institute, Bethesda, Maryland.
¹⁰ Yale University, New Haven, Connecticut.

PMID: 32506123
PMCID: PMC7566550
DOI: 10.1093/neuonc/noaa142

Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery

Stuart A Grossman et al. Neuro Oncol. 2020.

. 2020 Oct 14;22(10):1422-1424.

doi: 10.1093/neuonc/noaa142.

Authors

Stuart A Grossman¹, Carlos G Romo¹, Michelle A Rudek¹, Jeffrey Supko², Joy Fisher¹, L Burt Nabors³, Patrick Y Wen⁴, David M Peereboom⁵, Benjamin M Ellingson⁶, William Elmquist⁷, Fred G Barker², David Kamson¹, Jann N Sarkaria⁸, William Timmer⁹, Ranjit S Bindra¹⁰, Xiaobu Ye¹

Affiliations

¹ Johns Hopkins University, Baltimore, Maryland.
² Massachusetts General Hospital, Boston, Massachusetts.
³ University of Alabama Birmingham, Birmingham, Alabama.
⁴ Dana-Farber Cancer Institute, Boston, Massachusetts.
⁵ Cleveland Clinic, Cleveland, Ohio.
⁶ University of California Los Angeles, Los Angeles, California.
⁷ University of Minnesota, Minneapolis, Minnesota.
⁸ Mayo Clinic, Rochester, Minnesota.
⁹ National Cancer Institute, Bethesda, Maryland.
¹⁰ Yale University, New Haven, Connecticut.

PMID: 32506123
PMCID: PMC7566550
DOI: 10.1093/neuonc/noaa142

No abstract available

PubMed Disclaimer

References

1. Alexander BM, Cloughesy TF. Adult glioblastoma. J Clin Oncol. 2017;35(21):2402–2409. - PubMed
1. Pardridge WM. Blood-brain barrier delivery. Drug Discov Today. 2007;12(1-2):54–61. - PubMed
1. Heffron TP. Small molecule kinase inhibitors for the treatment of brain cancer. J Med Chem. 2016;59(22):10030–10066. - PubMed
1. Levin VA, Tonge PJ, Gallo JM, et al. CNS anticancer drug discovery and development conference white paper. Neuro Oncol. 2015;17(suppl 6):vi1–vi26. - PMC - PubMed
1. Levin VA, Abrey LE, Heffron TP, et al. CNS anticancer drug discovery and development: 2016 conference insights. CNS Oncol. 2017;6(3):167–177. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

LinkOut - more resources